SAN DIEGO, Nov. 17, 2016 /PRNewswire/ -- OncoSec
Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company
developing DNA-based intratumoral cancer immunotherapies, will
provide updates today on multiple key corporate initiatives at the
Company's inaugural Investor and Analyst Day in San Diego, CA, including plans for a melanoma
combination directed-registration study of OncoSec's lead product
candidate, ImmunoPulse® IL-12, in combination with anti-PD-1
therapy. In addition, the Company will provide details on its
preclinical multi-gene plasmid constructs, Tissue-based Real-time
Adaptive Controlled Electroporation (TRACE™), and
its Technology Access Program (TAP). OncoSec will also
highlight the new Phase II melanoma data that was recently
presented at the Society for Immunotherapy of Cancer Annual Meeting
("SITC 2016").
"By focusing our clinical programs on patients who do not
respond to anti-PD-1 therapy, we are committed to developing
therapies for those in critical need of alternative treatments,"
said Punit Dhillon, President and
CEO of OncoSec. "The favorable anti-tumor activity and safety data
garnered from the Investigator Sponsored Trial (IST) Phase II
clinical trial combining ImmunoPulse® IL-12 and
KEYTRUDA® (pembrolizumab) provides us with additional
confidence to move forward with key regulatory, clinical and
commercial efforts aimed at achieving marketing approval for
ImmunoPulse® IL-12 in anti-PD-1 non responder advanced
melanoma. We are pleased to be focused on a
registration-directed clinical program with a regulatory path that
we hope will lead to a potential FDA approval for our first
commercial product in 2019."
"We are changing the way clinicians and scientists think about
the use of technology to manipulate cellular activity with the
power of DNA construct delivery and activation through our
innovative, easy to use, next-generation gene electro-transfer
devices," continued Mr. Dhillon. "We believe our development
strategy for ImmunoPulse® IL-12 will lead to a large
market opportunity, and can generate significant value for
shareholders and provide a strong foundation for advancing
OncoSec's next clinical candidate in first-in-human studies in
2018."
A replay of the event webcast will be available shortly after
the meeting and can be accessed for up to 12 months through the
Events and Presentations section under the Investors tab of
OncoSec's website at www.oncosec.com.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse®IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as the
potential to initiate a systemic immune response. OncoSec's lead
program, ImmunoPulse®IL-12, is currently in clinical
development for several indications, including metastatic melanoma,
head and neck cancer, and triple-negative breast cancer. The
program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to
anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse®
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse®
platform. For more information, please visit www.oncosec.com.
OncoSec Medical Incorporated, Forward Looking
Statements
To the extent statements contained in this press
release are not descriptions of historical facts regarding OncoSec
Medical Incorporated, they may be considered forward looking
statements, as described in the Private Securities Litigation
Reform Act of 1995, reflecting management's current beliefs and
expectations. Forward looking statements speak only as of the date
they are made, and they are subject to known and unknown risks,
uncertainties, and other factors that may cause our or our
industry's actual results, levels of activity, performance or
achievements to be materially different from those anticipated by
such statements. You can identify forward-looking statements by
words such as "aimed at," "anticipate," "believe," "can," "could,"
"estimate," "expect," "focus," "intend," "may," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes. Forward looking
statements contained in this press release include, but are not
limited to, statements regarding: (i) the success and timing of our
product development activities and clinical trials; (ii) our
ability to develop and commercialize our product candidates; (iii)
our plans to research, discover, evaluate and develop additional
potential product, technology and business candidates and
opportunities; (iv) our and our partners' ability to develop,
manufacture and commercialize our product candidates and to improve
the manufacturing process; (v) the size and growth potential of the
markets for our product candidates, and our ability to serve those
markets; (vi) the rate and degree of acceptance of our product
candidates; (vii) our ability to attract and retain key scientific
or management personnel; (viii) the anticipated timing of clinical
data availability; (ix) the anticipated timing of commercial launch
of ImmunoPulse® IL-12; (x) our ability to meet our
milestones; (xi) our expectations regarding our ability to obtain
and maintain intellectual property protection; (xii) the level of
our corporate expenditures; (xiii) the assessment of our technology
by potential corporate partners; and, (xiv) the impact of capital
market conditions on our Company. Undue reliance should not be
placed on forward looking statements. Such statements are subject
to factors, risks and uncertainties, such as those described in our
periodic filings with the Securities and Exchange Commission,
including without limitation our Quarterly Reports on Form 10-Q,
our annual reports on Form 10-K and other filings. Various factors
may cause actual results to differ materially from those expressed
or implied by such forward looking statements. We undertake no
obligation to publicly update any forward-looking statements.
OncoSec's investigational drug and device products have not been
approved or cleared by the FDA.
CONTACT:
Sophia Ononye,
PhD MPH MBA
Associate Director, Investor Relations and Corporate
Communications
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-announces-key-corporate-initiatives-at-inaugural-investor--analyst-day-on-november-17-2016-300364825.html
SOURCE OncoSec Medical Incorporated